



The Best Diagnostic Solution for Invasive Candidiasis




INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST

Indirect chemiluminescent immunoassay (CLIA) to test IgG antibodies against antigens located on the cell wall surface of the micelium of *Candida albicans* (CAGTA *Candida albicans* germ tube antibody) in human serum/plasma.

PRODUCT FEATURES

- Discriminates between infection and colonization
- High Negative Predictive Value (NPV)
- Highly convenient solution to urgent samples
- Simple and automated protocol that provides results within 1 hour
- Sample dispensed from primary tube
- Objective method with extraordinary sensitivity and accuracy in the results
- Monotest format with ready-to-use reagents
- CAGTA (*Candida albicans* germ tube antibody) is widely recognized in the scientific literature as an excellent diagnostic tool



Ref. VCM094 - 24 tests

The Best Diagnostic Solution for Invasive Candidiasis

Invasive candidiasis

Candida yeasts normally live in and on the body without causing any symptoms with the exception of vaginitis and oral thrush. In people at risk, invasive candidiasis is an opportunistic disease of fungal etiology that can occur when *Candida* yeasts enter the bloodstream and spreads to other parts of the body causing an infection.

Patients at high risk for developing candidemia include:

- Intensive care unit (ICU) patients
- Long-stay hospitalized patients
- Surgical patients
- Patients with a central venous catheter
- People whose immune systems are weakened
- Patients receiving broad spectrum antibiotic therapy
- Very low-birth-weight infants

New test for the early detection of invasive candidiasis

Vircell has launched a new test for the early detection of invasive candidiasis (IC) that discriminates infection from colonization. A prompt and accurate diagnosis is essential as a delay of only 12 hours may affect survival significantly.

Patients with candidemia are at a very high risk of fatal outcome and samples analysis cannot wait. With this method, clinicians will be able to specifically treat the infective phase of *Candida*, avoiding for many patients to receive unnecessary, expensive and sometimes toxic antifungals.

INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST can bring significant advances to clinical laboratories where giving an informed result can truly make the difference in saving someone's life.

Why INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST

should be part of the routine of laboratories dealing with samples from people at risk of IC?

✓ Results in 1 hour

Early diagnosis and treatment are associated with a better prognosis in invasive candidiasis

✓ Monotest format

All reagents are included and ready-to-use

✓ Better patient care

Giving unnecessary and expensive antifungal drugs to patients should be avoided

✓ Save costs

Using the right diagnostic tool could lead to substantial reductions in total inpatient cost

